EFETIVIDADE DAS POLÍTICAS PÚBLICAS NA MITIGAÇÃO DOS RISCOS DE ROUBO DE CARGA NO OESTE DO PARANÁ

O presente artigo não tem a pretensão de esgotar o tema nem alinhar certezas sobre o problema de pesquisa apresentado. Buscou-se tecer reflexões e analisar de forma exploratória o impacto das políticas públicas no combate ao roubo de carga no Brasil e no Oeste do Paraná, ponderando-se sobre os custos para as transportadoras de pequeno porte para a mitigação dos riscos de prejuízos advindos desta modalidade criminosa. Para tanto, realizou-se um levantamento bibliográfico sobre o tema nas principais bases de dados, buscando-se estudos recentes acerca do problema investigado, além de coletas de dados estatísticos de roubo de carga nas bases da Confederação Nacional de Transportes e Sindicato do Comércio Atacadista de Gêneros Alimentícios do Estado do Paraná. Já a legislação vigente e demais políticas públicas foram pesquisadas nos sites oficiais dos Poderes Públicos. Concomitantemente, estudou-se brevemente o perfil do crime de roubo de carga no Paraná, com base nas informações repassadas pela Polícia Rodoviária Federal. Para a análise de custos operacionais visando a mitigação dos riscos de roubo de carga, realizou-se um levantamento do balanço contábil financeiro de uma transportadora de pequeno porte do Oeste do Paraná. Como resultados da pesquisa, verificou-se que as Políticas Públicas do Brasil e do Paraná demonstram-se embrionárias, ineficazes e ineficientes para a diminuição dos índices de roubo de carga, impactando na majoração dos custos operacionais de transportadoras de pequeno porte

Frequency of TERT promoter mutations in human cancers

Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations. Both in thyroid cancers and glioblastoma, TERT promoter mutations are significantly associated with older age of the patients. Our results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase.We thank to Mrs Mafalda Rocha for the excellent technical support in the sequencing work. This work was partially supported by the Portuguese Science and Technology Foundation (FCT) through BPD (SFRH/BPD/85249/2012 to H. P.), PhD (SFRH/BD/81940/2011 to J.V. and SFRH/BD/79135/2011 to A. A.) and BI grants, and the grant through the Program Ciencia 2008 (J.L.) and the project (PIC/IC/83037/2007). Further funding was obtained from the project 'Microenvironment, metabolism and cancer' partially supported by Programa Operacional Regional do Norte (ON.2-O Novo Norte), under the Quadro de Referencia Estrategico Nacional (QREN), and through the Fundo Europeu de Desenvolvimento Regional (FEDER). IPATIMUP is an associate laboratory of the Portuguese Ministry of Science, Technology and Higher Education and is partially supported by the FCT

Multiple Myeloma Treatment Guidelines by the Portuguese Group of Multiple Myeloma

The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in recent years and the attention given to the characteristics of patients have allowed the reduction of toxicities and increased survival and quality of life of patients with multiple myeloma. These treatment recommendations from the Portuguese Multiple Myeloma Group offer guidance for first-line treatment and progression/relapse situations. These recommendations are given highlighting the data that justify each choice and referring to the respective levels of evidence that support these options. Whenever possible, the respective national regulatory framework is presented. These recommendations constitute an advance towards the best treatment of multiple myeloma in Portugal.publishersversionpublishe